BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/19/2026 7:28:08 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-03-03 03:37 |
|
Peer-Review Started |
|
2026-03-03 03:38 |
|
First Decision by Editorial Office Director |
|
2026-03-09 08:37 |
|
Return for Revision |
|
2026-03-09 08:37 |
|
Revised |
|
2026-03-18 08:08 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-08-27 02:44 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-08-28 09:10 |
|
Articles in Press |
|
2026-08-28 09:10 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-09-23 02:04 |
|
Publish the Manuscript Online |
|
2026-10-19 07:28 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Opinion Review |
| Article Title |
Evolving landscape of biomarkers in colorectal cancer: From interleukin-8 to integrated multi-marker strategies
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Nabil Ismaili |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nabil Ismaili, Chairman, Chief Pharmacist, Professor, Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Mohammed VI Foundation of Sciences and Health (FM6SS), Mohammed Taïeb Naciri Street, Anfa City, Hay Hassan Municipality, Casablanca 82403, Casablanca-Settat, Morocco. nismaili@um6ss.ma |
| Key Words |
Colorectal cancer; Interleukin-8; Biomarkers; Circulating tumor DNA; Carcinoembryonic antigen; Minimal residual disease; Liquid biopsy; Precision oncology; Methylation; Tumor microenvironment |
| Core Tip |
Serum interleukin-8 (IL-8) levels are significantly elevated in patients with colorectal cancer and demonstrate moderate diagnostic accuracy (area under the curve, 0.68). Given this modest discriminatory performance and the absence of external validation, IL-8 does not currently meet the criteria for clinical implementation as a standalone diagnostic biomarker. Although IL-8 has shown independent associations in multivariate analyses, its clinical role remains investigational. Within the evolving biomarker landscape, where mismatch repair status, perioperative carcinoembryonic antigen, and postoperative circulating tumor DNA currently have stronger supportive evidence, IL-8 should be regarded as an investigational biomarker requiring prospective validation before clinical integration. No study to date has demonstrated that IL-8-guided strategies improve clinical outcomes in patients with colorectal cancer. |
| Publish Date |
2026-10-19 07:28 |
| Citation |
Ismaili N. Evolving landscape of biomarkers in colorectal cancer: From interleukin-8 to integrated multi-marker strategies. World J Gastrointest Surg 2026; 18(10): 120555
|
| URL |
https://www.wjgnet.com/1948-9366/full/v18/i10/120555.htm |
| DOI |
https://doi.org/10.4240/wjgs.120555 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
